首页> 中文期刊> 《中国医刊》 >Bax蛋白表达与中国人群前列腺癌风险相关性的Meta分析

Bax蛋白表达与中国人群前列腺癌风险相关性的Meta分析

         

摘要

Objective To systematically review the correlation between Bax expression and prostate cancer, as well as its clinicopathologic features in Chinese population. Method Such databases as PubMed, Embase, CBM, CNKI, VIP, and WanFang Data were electronically searched from inception to October, 2016 to collect case-control studies about the correlation between Bax expression and prostate cancer, as well as its clinicopathologic features in Chinese population. Two reviewers independently screened literature, extracted data and assessed the methodological quality of included studies. Then, meta-analysis was performed using RevMan 5.3 software. Result A total of 8 case-control studies were included, involving 331 prostate cancer cases, 129 benign prostatic hyperplasia cases, and 138 controls. The results of meta-analysis showed that no significant association between the prostate cancer group and the benign prostatic hyperplasia group (OR=1.41, 95%CI: 0.30-6.49, P=0.66), but the prostate cancer group had a significant lower expression compared with the control group (OR=0.27, 95%CI: 0.06-1.18, P=0.08). Moreover, there was no significant association of the expression level of Bax in the different clinicopathologic features. Conclusion Current evidence suggests that the expression level of Bax is not significantly correlated with prostate cancer and its clinicopathologic features in Chinese population. Due to limited quantity and quality of included studies, the above conclusions need to be verified by conducting more high quality and large sample size studies.%目的 系统评价Bax蛋白表达与中国人群前列腺癌及其不同临床病理特征的相关性.方法 计算机检索PubMed、Embase、CBM、CNKI、VIP和WanFang Data数据库,查找关于Bax蛋白表达与中国人群前列腺癌及其不同临床病理特征相关性的病例-对照研究,检索时限均为从建库至2016年10月.由2位评价者独立进行文献筛选、资料提取和方法学质量评价,然后采用RevMan 5.3软件进行Meta分析.结果 最终纳入8个病例-对照研究,其中前列腺癌患者331例,前列腺增生患者129例,正常前列腺对照138例.Meta分析结果显示:前列腺癌患者Bax蛋白的表达量与前列腺增生患者无差异(OR=1.41,95%CI:0.30~6.49,P=0.66),正常前列腺对照组的差异无显著性(OR=0.27,95%CI:0.06~1.18,P=0.08);此外,Bax蛋白表达在前列腺癌不同临床病理特征中亦无差异.结论 Bax蛋白表达与中国人群前列腺癌发病风险及其临床病理特征无显著相关性.受纳入研究样本量和质量的限制,上述结论需进一步开展大样本、高质量研究加以验证.

著录项

  • 来源
    《中国医刊》 |2017年第8期|55-58|共4页
  • 作者单位

    武汉大学中南医院 泌尿外科,湖北 武汉 430071;

    武汉大学中南医院 泌尿外科,湖北 武汉 430071;

    武汉大学中南医院 泌尿外科,湖北 武汉 430071;

    武汉大学中南医院 泌尿外科,湖北 武汉 430071;

    武汉大学中南医院 泌尿外科,湖北 武汉 430071;

    武汉大学中南医院 生物样本库,湖北 武汉 430071;

    武汉大学循证与转化医学中心,湖北 武汉 430071;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 前列腺肿瘤;
  • 关键词

    前列腺癌; Bax蛋白; Meta分析;

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号